SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Chakrabarty S)
 

Search: WFRF:(Chakrabarty S) > Different aspects o...

Different aspects of Alzheimer's disease-related amyloid beta-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia

Thal, D. R. (author)
Ronisz, A. (author)
Tousseyn, T. (author)
show more...
Upadhaya, A. R. (author)
Balakrishnan, K. (author)
Vandenberghe, R. (author)
Vandenbulcke, M. (author)
von Arnim, C. A. F. (author)
Otto, M. (author)
Beach, T. G. (author)
Lilja, J. (author)
Heurling, Kerstin (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Wallenberg Centre for Molecular and Translational Medicine,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Chakrabarty, A. (author)
Ismail, A. (author)
Buckley, C. (author)
Smith, A. P. L. (author)
Kumar, S. (author)
Farrar, G. (author)
Walter, J. (author)
show less...
 (creator_code:org_t)
2019-11-14
2019
English.
In: Acta Neuropathologica Communications. - : Springer Science and Business Media LLC. - 2051-5960. ; 7:1
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Alzheimer's disease (AD)-related amyloid beta-peptide (A beta) pathology in the form of amyloid plaques and cerebral amyloid angiopathy (CAA) spreads in its topographical distribution, increases in quantity, and undergoes qualitative changes in its composition of modified A beta species throughout the pathogenesis of AD. It is not clear which of these aspects of A beta pathology contribute to AD progression and to what extent amyloid positron emission tomography (PET) reflects each of these aspects. To address these questions three cohorts of human autopsy cases (in total n = 271) were neuropathologically and biochemically examined for the topographical distribution of A beta pathology (plaques and CAA), its quantity and its composition. These parameters were compared with neurofibrillary tangle (NFT) and neuritic plaque pathology, the degree of dementia and the results from [F-18]flutemetamol amyloid PET imaging in cohort 3. All three aspects of A beta pathology correlated with one another, the estimation of A beta pathology by [F-18]flutemetamol PET, AD-related NFT pathology, neuritic plaques, and with the degree of dementia. These results show that one aspect of A beta pathology can be used to predict the other two, and correlates well with the development of dementia, advancing NFT and neuritic plaque pathology. Moreover, amyloid PET estimates all three aspects of A beta pathology in-vivo. Accordingly, amyloid PET-based estimates for staging of amyloid pathology indicate the progression status of amyloid pathology in general and, in doing so, also of AD pathology. Only 7.75% of our cases deviated from this general association.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Keyword

Alzheimer's disease
Amyloid beta peptide
Staging
Amyloid load
Soluble amyloid
Insoluble amyloid
Amyloid maturation
Amyloid PET
[F-18]flutemetamol
a-beta
neuropathologic assessment
neurofibrillary tangles
cognitive
impairment
national institute
senile plaques
human brain
pet
deposition
angiopathy
Neurosciences & Neurology

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view